Geneva, Switzerland, 06 July, 2016 – ObsEva, a Swiss biopharmaceutical company innovating women’s reproductive health and pregnancy therapeutics, today announced that its…
Category: Content
This category defines content that can be used throughout the website. So for example an article, a report, a file,… i.e. a press release can be displayed on the “press release” page but the newest press release is also displayed on the homepage.
Bio€quity Europe 2016
ObsEva CEO & Co-Founder Ernest Loumaye will be presenting at Bio€quity Europe 2016 http://www.biocentury.com/conferences/bioequityeurope/dates Date & Time: 10 May 2016 –…
15th Annual Needham Healthcare Conference
ObsEva CEO & Co-Founder Ernest Loumaye will be presenting at the 15th Annual Needham Healthcare Conference To listen to the…
ObsEva to Webcast Presentation at 15th Annual Needham Healthcare Conference
Geneva, Switzerland, 05 April, 2016 – ObsEva, a Swiss biopharmaceutical company innovating women’s reproductive health and pregnancy therapeutics, today announced that Ernest Loumaye,…
ObsEva Strengthens Board with Appointment of Biotechnology Veteran Dr. Frank Verwiel
Geneva, Switzerland, 24 March 2016 – ObsEva, a Swiss biopharmaceutical company innovating women’s reproductive health and pregnancy therapeutics, today announced…
The OTR Antagonist, OBE001, Inhibits Both Spontaneous and OT-Induced Contractions of Human Pregnant Myometrium In Vitro
Shankari Arulkumaran, Sung Hye Kim, Oliver Pohl, Andre Chollet, Phillip R. Bennett and Vasso Terzidou
SRI Conference, 16-19 March 2016, Montreal, Canada
Abstract S-096
Scientific Abstracts. (2016). Reproductive Sciences, 23(1_suppl), 51A-344A
The OTR Antagonist, OBE001, Inhibits OT-Driven Proinflammatory Effects in Both Human Myometrium and Amnion
Sung Hye Kim, Oliver Pohl, Andre Chollet, Adam Fairhurst, Phillip R Bennett, Vasso Terzidou
SRI Conference, 16-19 March 2016, Montreal, Canada
Abstract T-071: Page 123A
Scientific Abstracts. (2016). Reproductive Sciences, 23(1_suppl), 51A-344A
The OTR Antagonist, OBE001, Suppresses the Effects of OT on miRNA Expression in Human Myometrium
Sung Hye Kim, Stacey Robinson, Joanna Cook, Oliver Pohl, Andre Chollet, Phillip R Bennett, Vasso Terzidou
SRI Conference, 16-19 March 2016, Montreal, Canada
Abstract F-061
Scientific Abstracts. (2016). Reproductive Sciences, 23(1_suppl), 51A-344A
ObsEva Closes CHF 60 (USD 60) Million in Series B Financing
Geneva, Switzerland, 23 November 2015 – ObsEva, a Swiss biopharmaceutical company developing a novel generation of drugs addressing serious conditions compromising…
ObsEva and Kissei Pharmaceutical Announce Global Agreement to Develop and Commercialize KLH-2109 for the Treatment of Endometriosis
Geneva, Switzerland, 20 November 2015 – ObsEva and Kissei Pharmaceutical Co., Ltd. (“Kissei”) today announced that they have entered into a…